CoChat

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease

Open access
Joseph‐Mathurin, Nelly, Llibre‐Guerra, Jorge J., Li, Yan, McCullough, Austin A., Hofmann, Carsten, Wojtowicz, Jakub, Park, Ethan, Wang, Guoqiao, Preboske, Gregory M., Wang, Qing, Gordon, Brian A., Chen, Charles D., Flores, Shaney, Aggarwal, Neelum T., Berman, Sarah B., Bird, Thomas D., Black, Sandra E., Borowski, Bret, Brooks, William S., Chhatwal, Jasmeer P., Clarnette, Roger, Cruchaga, Carlos, Fagan, Anne M., Farlow, Martin, Fox, Nick C., Gauthier, Serge, Hassenstab, Jason, Hobbs, Diana A., Holdridge, Karen C., Honig, Lawrence S., Hornbeck, Russ C., Hsiung, Ging‐Yuek R., Jack, Clifford R., Jimenez‐Velazquez, Ivonne Z., Jucker, Mathias, Klein, Gregory, Levin, Johannes, Mancini, Michele, Masellis, Mario, McKay, Nicole S., Mummery, Catherine J., Ringman, John M., Shimada, Hiroyuki, Snider, B. Joy, Suzuki, Kazushi, Wallon, David, Xiong, Chengjie, Yaari, Roy, McDade, Eric, Perrin, Richard J., Bateman, Randall J., Salloway, Stephen P., Benzinger, Tammie L.S., Clifford, David B., For the Dominantly Inherited Alzheimer Network Trials Unit · 2022 · Annals of Neurology
Cited by 47

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Objective: To determine the characteristics of participants with amyloid‐related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD). Methods: 142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β‐amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross‐sectional and longitudinal analyses evaluated potential ARIA‐related risk factors. Results: Eleven participants developed ARIA‐E, including 3 with mild symptoms. No ARIA‐E was reported under solanezumab while gantenerumab was associated with ARIA‐E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE‐ɛ4 carriers were more likely to develop ARIA‐E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA‐E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA‐E occurrence, all ARIA‐E participants were amyloid‐PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA‐H. Most ARIA‐E radiologically resolved after dose adjustment and developing ARIA‐E did not significantly increase odds of trial discontinuation. ARIA‐E was more frequently observed in the occipital lobe (90%). ARIA‐E severity was associated with age at time of ARIA‐E. Interpretation: In DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA‐E risk, with additional risk for individuals APOE‐ɛ4(+) or with microhemorrhage. ARIA‐E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729–744

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.26511

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

Metadata

Authors
Joseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wang, Q., Gordon, B. A., Chen, C. D., Flores, S., Aggarwal, N. T., Berman, S. B., Bird, T. D., Black, S. E., Borowski, B., Brooks, W. S., Chhatwal, J. P., Clarnette, R., Cruchaga, C., Fagan, A. M., Farlow, M., Fox, N. C., Gauthier, S., Hassenstab, J., Hobbs, D. A., Holdridge, K. C., Honig, L. S., Hornbeck, R. C., Hsiung, G. R., Jack, C. R., Jimenez‐Velazquez, I. Z., Jucker, M., Klein, G., Levin, J., Mancini, M., Masellis, M., McKay, N. S., Mummery, C. J., Ringman, J. M., Shimada, H., Snider, B. J., Suzuki, K., Wallon, D., Xiong, C., Yaari, R., McDade, E., Perrin, R. J., Bateman, R. J., Salloway, S. P., Benzinger, T. L. S., Clifford, D. B., & For the Dominantly Inherited Alzheimer Network Trials Unit
Venue
Annals of Neurology
Publisher
Wiley
Published
2022-10-13
Volume
92
Issue
5
Pages
729-744
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W4296982306
Cited by
47
References
20
FWCI
4.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.